FORM 4

# **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

O	MB	AP	PR	O\	/AI

	OMB Number:	3235-0287
l	Estimated average burden	
l	hours per response:	0.5

#### Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

# STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person *  MONAHAN JOHN J			2. Issuer Name and Ticker or Trading Symbol HEAT BIOLOGICS, INC. [ HTBX ]		tionship of Reporting Person(s) all applicable) Director	to Issuer	
(Last) (First) (Middle)		(Middle)	3. Date of Earliest Transaction (Month/Day/Year) 04/28/2017		Officer (give title below)	Other (specify below)	
C/O HEAT BIOLOGICS, INC. 801 CAPITOLA DRIVE			4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Indivi	ndividual or Joint/Group Filing (Check Applicable Line)  X Form filed by One Reporting Person Form filed by More than One Reporting Person		
DURHAM	(Street) DURHAM NC 277						
(City)	(State)	(Zip)					

#### Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transac Code (Ir 8)	tion	4. Securities Ac Disposed Of (D)			Securities Beneficially Owned Following Reported	(Instr. 4)	Beneficial Ownership
			Code	v	Amount	(A) or (D)	Price	Transaction(s) (Instr. 3 and 4)		(Instr. 4)
Common Stock	04/28/2017		A		3,958(1)(2)	A	(1)(2)	5,169(1)(2)	D	

# Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

- 1	1. Title of	2.	3. Transaction	3A. Deemed	4.		5. Num	ber of	6. Date Exerc	isable and	7. Title and A	mount of	8. Price of	9. Number of	10.	11. Nature
- 1	Derivative	Conversion	Date	Execution Date,	Transac	tion	Derivat	ive	Expiration Da	ate	Securities Un	nderlying	Derivative	derivative	Ownership	of Indirect
- 1	Security (Instr. 3)	or Exercise	(Month/Day/Year)	if any	Code (In	ıstr.	Securit	ies	(Month/Day/Y	'ear)	Derivative Se	curity	Security	Securities	Form:	Beneficial
- 1		Price of		(Month/Day/Year)	8)		Acquire	ed (A)			(Instr. 3 and	4)	(Instr. 5)	Beneficially	Direct (D)	Ownership
- 1		Derivative					or Disp	osed of						Owned	or Indirect	(Instr. 4)
- 1		Security					(D) (Ins	tr. 3, 4						Following	(I) (Instr. 4)	
- 1							and 5)							Reported		
- 1													1	Transaction(s)		
- 1						l						Amount		(Instr. 4)		
-1						l						or				
-1						l			Date	Expiration		Number				
L					Code	٧	(A)	(D)	Exercisable	Date	Title	of Shares				

### Explanation of Responses:

- 1. On March 7, 2017, Heat Biologics, Inc. (the "Company") entered into a Stock Purchase Agreement, as amended, with Pelican Therapeutics, Inc. ("Pelican"), and certain holders of the outstanding capital stock of Pelican, including the reporting person, who agreed to sell their shares in Pelican to the Company (the "Acquisition"). The reporting person is a member of the Company's board of directors.
- 2. (Continued from footnote (1)) In connection with the closing of the Acquisition, which occurred on April 28, 2017, the reporting person sold approximately 85% of his shares of capital stock in Pelican held through a limited liability company in exchange for cash consideration and 3,958 shares of the Company's common stock, \$0.0002 par value per share (the "Common Stock"). All of the shares of Common Stock issued in the Acquisition are currently held in escrow and are subject to forfeiture during the six month period following the Acquisition to satisfy certain indemnification obligations.

05/02/2017 /s/ John Monahan

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.